COVID-19在神经内分泌肿瘤患者中的表现：INTENSIVE研究的两年结果。
COVID-19 in patients with neuroendocrine neoplasms: two-year results of the INTENSIVE study.
发表日期：2023 Mar 01
作者：
Nicola Fazio, Lorenzo Gervaso, Thorvardur R Halfdanarson, Mohamad Sonbol, Rachel A Eiring, Sara Pusceddu, Natalie Prinzi, Benedetta Lombardi Stocchetti, Simona Grozinsky-Glasberg, David J Gross, Thomas Walter, Patrick Robelin, Catherine Lombard-Bohas, Samuele Frassoni, Vincenzo Bagnardi, Lorenzo Antonuzzo, Clotilde Sparano, Sara Massironi, Fabio Gelsomino, Alberto Bongiovanni, Nicoletta Ranallo, Salvatore Tafuto, Maura Rossi, Mauro Cives, Kakil Ibrahim Rasul, Hytham Hamid, Alessandra Chirco, Michela Squadroni, Anna La Salvia, Jorge Hernando, Johannes Hofland, Anna Koumarianou, Sabrina Boselli, Darina Tamayo, Cristina Mazzon, Manila Rubino, Francesca Spada
来源：
ENDOCRINE-RELATED CANCER
摘要：
关于INTENSIVE研究中的85名患者的初步结果已于2021年发布。现在我们正在报告2年分析。我们对神经内分泌肿瘤（NENs）和分子证实的SARS-CoV-2阳性的患者进行了一项前瞻性/回顾性的全球性研究。在此，我们报告的是自2020年6月1日至2022年5月31日期间连续入选的患者的数据。在118个接触中心中，有25个处于活动状态，19个正在积极招募患者，共有280名患者入选。2020年有47.5％的患者SARS-CoV-2阳性，2021年为35.1％，2022年为17.4％。COVID-19诊断的中位数年龄为60岁。优分化的肿瘤、非功能性、转移期和胃肠胰（GEP）原发部位占NEN的大部分。总体中，与COVID-19相关的肺炎发生在22.8％的患者中，其中61.3％需要住院； 11名患者（3.9％）需要亚重症或重症监护室治疗，而14名患者死亡（5％），其中11例（3.9％）直接与COVID-19有关。胸部和其他NEN原发部位与COVID-19住院治疗和亚重症或重症监护室有关。2022年的住院和肺炎数量显著降低，与2020年相比。在我们最大的NEN患者COVID-19系列中，无论COVID-19如何，NEN人群与普通人群相似。但是，应仔细考虑年龄较大、非GEP原发部位和糖尿病的患者对COVID-19发病率和死亡率的升高。通过将我们的结果与包括其他癌症患者和COVID-19病例登记在内的NEN患者进行整合，可以获得相关信息。
Preliminary results regarding 85 patients of the INTENSIVE study have been published in 2021. Now we are reporting the 2-year analysis. We conducted a retrospective/prospective worldwide study on patients with neuroendocrine neoplasms (NENs) and a molecularly proven SARS-CoV-2 positivity. Here we are reporting data from consecutive patients enrolled between June 01, 2020, and May 31, 2022. Among the 118 contacted centers, 25 were active to enroll and 19 actively recruiting at the time of data cut-off for a total of 280 patients enrolled. SARS-CoV-2 positivity occurred in 47.5% of patients in 2020, 35.1% in 2021 and 17.4% in 2022. Median age at COVID-19 diagnosis was 60 years. Well differentiated tumors, non-functioning, metastatic stage and gastroenteropancreatic (GEP) primary site represented most of NENs. COVID-19-related pneumonia occurred in 22.8% of the total, with 61.3% of them requiring hospitalization; 11 patients (3.9%) needed sub-intensive or intensive care unit therapies and 14 patients died (5%), in 11 cases (3.9%) directly related to COVID-19. Thoracic and other NEN primary site were associated with hospitalization for COVID-19 and with sub-intensive or intensive care. A significant decrease in both hospitalization and pneumonia occurred in 2022 versus 2020. In our largest series of NEN patients with COVID-19, the NEN population is similar to the general population regardless of COVID-19. However, older age, non-GEP primary sites and diabetes mellitus should be carefully considered for increased COVID-19 morbidity and mortality. Relevant information could be derived by integrating our results with NENs patients included in other cancer patients and COVID-19 registries.